Edition:
United States

Takeda Pharmaceutical Co Ltd (TKPYY.PK)

TKPYY.PK on OTC Markets Group

26.83USD
17 Aug 2017
Change (% chg)

$-0.26 (-0.96%)
Prev Close
$27.09
Open
$27.00
Day's High
$27.02
Day's Low
$26.83
Volume
24,928
Avg. Vol
50,693
52-wk High
$27.35
52-wk Low
$19.96

TKPYY.PK

Chart for TKPYY.PK

About

Takeda Pharmaceutical Company Limited is a Japan-based company engaged in the pharmaceutical business. The Ethical Pharmaceutical segment is engaged in the manufacture and sale of pharmaceutical products, such as therapeutic substances for diabetes, circulatory drugs, anticancer drugs, drugs for central neurological diseases,... (more)
No analyst recommendations are available for TKPYY.PK.

Overall

No Ratios Available.

Financials

  TKPYY.PK Industry Sector
P/E (TTM): -- 31.64 32.84
EPS (TTM): -- -- --
ROI: -- 15.30 14.86
ROE: -- 16.32 16.11

BRIEF-Takeda Pharmaceutical Co reports 10.9 pct stake in Molecular Templates - SEC Filing‍​

* Takeda Pharmaceutical Company reports 10.9 percent stake in Molecular Templates Inc as of August 1, 2017 - SEC Filing‍​ Source text: (http://bit.ly/2vTAtQL) Further company coverage:

Aug 10 2017

BRIEF-Takeda and Shattuck Labs announce research collaboration

* Takeda and Shattuck Labs announce research collaboration to explore agonist redirected checkpoint fusion proteins in immuno-oncology

Aug 10 2017

BRIEF-Takeda and Cardurion Pharmaceuticals launch cardiovascular development partnership

* Takeda and Cardurion Pharmaceuticals launch cardiovascular development partnership

Aug 02 2017

UPDATE 1-Japanese drugmaker Takeda posts stronger profit as U.S. sales jump

* Astellas Q1 operating profit halves from year ago (Adds wider industry context, Astellas results)

Jul 28 2017

BRIEF-Takeda, Schrödinger announce multi-year, multi-target research collaboration

* Takeda and Schrödinger announce multi-year, multi-target research collaboration

Jul 20 2017

U.S. court upholds Takeda patent on cancer drug Velcade

A U.S. appeals court ruled on Monday that a patent on Takeda Pharmaceutical Co Ltd's cancer treatment Velcade is valid, pushing back the date when generic drug makers including Teva Pharmaceutical Industries Ltd and Mylan NV will be allowed to launch lower-cost versions of the drug in the United States.

Jul 17 2017

BRIEF-Selexis announces commercial license agreement with Takeda

* Selexis announces commercial license agreement with Takeda for the development of fusion proteins Source text for Eikon:

Jun 27 2017

CORRECTED-UPDATE 1-Seattle Genetics, Takeda lymphoma drug success fails to impress investors

June 26 Seattle Genetics Inc and Japan's Takeda Pharmaceutical Co Ltd said on Monday that their drug met the main goal in a late-stage study of helping blood cancer patients live longer without their condition worsening.

Jun 26 2017

CORRECTED-Seattle Genetics, Takeda lymphoma drug succeeds late-stage trial

June 26 Seattle Genetics Inc and Japan's Takeda Pharmaceutical Co Ltd said on Monday that their drug met the main goal in a late-stage study of helping blood cancer patients live longer without their condition worsening.

Jun 26 2017

BRIEF-Takeda and Seattle Genetics announce positive results from phase 3 ECHELON-1 clinical trial

* Takeda and Seattle Genetics announce positive results from phase 3 ECHELON-1 clinical trial evaluating Adcetris in frontline advanced hodgkin lymphoma

Jun 26 2017

Earnings vs. Estimates

No consensus analysis data available.